Nurix Therapeutics Announces Sanofi's Decision to Discontinue Development of STAT6 Degrader SAR448272
Sanofi has decided to discontinue the development of the STAT6 degrader SAR448272, a program previously partnered with Nurix Therapeutics.
Stocks · News reference
Sanofi CEO Belen Garijo Says Beyond 2030, Expect Total Revenues To Be Impacted Only Moderately By Dupixent's Loss Of Exclusivity
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Sickle Cell Disease Clinical Trial Pipeline Gains Momentum: 45+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight
Over 45 pharmaceutical companies are advancing 50+ pipeline drugs for sickle cell disease treatment. Key developments include Agios Pharmaceuticals' mitapivat receiving FDA Priority Review, Novo Nordisk's etavopivat meeting Phase III endpoints, and CorrectSequence Therapeutics' CS-206 showing sustained vaso-occlusive crisis-free results. The pipeline features diverse mechanisms including PK activators, gene therapies, and fetal hemoglobin stimulants, with approximately 5+ drugs in late-stage development.
Analysts Adjust Sanofi 12-Month Price Target
Sanofi's average 12-month price target has been adjusted by analysts to $50.20, reflecting a potential 10% upside from the previous closing price.
BTK Inhibitors Market to Expand During the Forecast Period (2026–2036) as Targeted Treatments Advance Across B-Cell Malignancies and Autoimmune Disorders | DelveInsight
The BTK inhibitors market is expected to experience steady growth through 2036, driven by increasing prevalence of B-cell malignancies, established clinical benefits, and an expanding pipeline of next-generation therapies. Key developments include FDA approvals for new indications and multiple drugs in clinical trials targeting oncology and autoimmune diseases across the 7MM markets.
RBC Capital Markets Raises Price Target on Sanofi
RBC Capital Markets has increased its price target for Sanofi shares from EUR 75 to EUR 80 while maintaining a 'Sector Perform' rating.
Regeneron Eyes One of Its Strongest Years Ever, Stock Jumps
Regeneron stock hits a 52-week high as earnings surge 70%, revenue jumps 36% and key drugs deliver record sales.